ALIBABA-CLOUD
10.1.2023 07:01:39 CET | Business Wire | Press release
Alibaba Cloud, the digital technology and intelligence backbone of Alibaba Group, has announced the launch of Apsara Developer Community, a new hub created to support global developers through an enhanced provision of diverse developer tools and resources. It aims to support the continuous growth of the developer community, while facilitating the further progress of the digital economy across markets.
“The developer community is an integral part of Alibaba Cloud’s ecosystem. We hope to grow together with our developers by providing the latest technologies, ecosystem resources and business collaboration opportunities,” said Selina Yuan, Vice President of Alibaba Group and President of Alibaba Cloud Intelligence International Business Unit.
New and Enhanced Community Resources, Competitions and Scholarship for Global Developers
Unveiled at Alibaba Cloud’s Global Developer Summit at Jakarta today, The Apsara Developer Community offers global developers resources and insights into the rising technology trends ranging from Web3, AI to digital intelligence. These resources include access to a slew of new development tools and latest projects, training materials and tutorials, forums and blogs, community events and competitions to showcase their application development, and other upskilling and networking opportunities.
The cloud leader also announced its latest competition, PolarDB Global Hackathon 2023, to encourage developers to explore cloud-native database innovations. From now until February 28, participants can submit their projects and winners will be awarded with a total of US$30,000 in cash prizes.
In addition, Alibaba Cloud also unveiled the Alibaba SMART Scholarship, which aims to encourage students to join the developer community with cloud-based technologies and become local digital talents. During the first year of this annual scholarship program, 20 interns from universities will be recruited to join Alibaba Cloud’s local offices to gain more field experience.
New Solution to Facilitate Superapp Development
With the rise of superapps – apps that include a range of independently developed miniapps to cater for different user requirements – Alibaba Cloud also unveiled a new solution to help developers build superapps cost-effectively and efficiently. Leveraging Alibaba Cloud’s Enterprise Mobile Application Studio (EMAS), the solution aims to enable developers to swiftly build superapps with rich platform capabilities within hours, adding competitive advantages for global organisations and enterprises.
Derived from the best practices of Alibaba’s e-commerce superapps Taobao and Tmall, the comprehensive solution provides developers with a rich ecosystem, including components for app infrastructure and business features, containers for running miniapps, and services for DevOps and operations.
“We believe our proven technologies and experience in supporting successful superapps can be beneficial for worldwide developers who are looking to create their own superapps and corresponding platform ecosystem,” said Raymond Xiao, Head of International Industry Solutions and Architecture at Alibaba Cloud Intelligence. “We can co-create more innovative technologies and solutions together with our developers, boosting further growth of the developer community.”
Alibaba Cloud is dedicated to contributing to the developer ecosystem including the open-source community. Alibaba Cloud, with over 30,000 contributors, has contributed to over 2,700 open-source projects on Github. The leading cloud provider is also a key member in various open-source communities such as Cloud Native Computing Foundation (CNCF), The Linux Foundation and RISC-V International.
About Alibaba Cloud
Established in 2009, Alibaba Cloud (www.alibabacloud.com) is the digital technology and intelligence backbone of Alibaba Group. It offers a complete suite of cloud services to customers worldwide, including elastic computing, database, storage, network virtualization services, large-scale computing, security, management and application services, big data analytics, a machine learning platform and IoT services. Alibaba Cloud is China’s leading provider of public cloud services by revenue in 2019, including PaaS and IaaS services, according to IDC. Alibaba Group is the world’s third leading and Asia Pacific’s leading IaaS provider by revenue in 2020 in U.S. dollars, according to Gartner’s April 2021 report.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230109005670/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom